480 related articles for article (PubMed ID: 25006133)
1. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
2. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
3. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
4. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
Jiang W; Zhang C; Tian Z; Zhang J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
[TBL] [Abstract][Full Text] [Related]
5. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
6. Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function.
Zhang C; Kadu S; Xiao Y; Johnson O; Kelly A; O'Connor RS; Lai M; Kong H; Srivatsa S; Tai V; Greenblatt E; Holmes M; Riley JL; June CH; Sheppard NC
Cancer Immunol Res; 2023 Nov; 11(11):1524-1537. PubMed ID: 37649085
[TBL] [Abstract][Full Text] [Related]
7. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Fujisaki H; Kakuda H; Shimasaki N; Imai C; Ma J; Lockey T; Eldridge P; Leung WH; Campana D
Cancer Res; 2009 May; 69(9):4010-7. PubMed ID: 19383914
[TBL] [Abstract][Full Text] [Related]
8. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.
Sahm C; Schönfeld K; Wels WS
Cancer Immunol Immunother; 2012 Sep; 61(9):1451-61. PubMed ID: 22310931
[TBL] [Abstract][Full Text] [Related]
9. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
10. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
[TBL] [Abstract][Full Text] [Related]
11. Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15 - Implications for Clinical Trials.
Törnroos H; Hägerstrand H; Lindqvist C
Anticancer Res; 2019 Jan; 39(1):107-112. PubMed ID: 30591446
[TBL] [Abstract][Full Text] [Related]
12. Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.
van Hees EP; Morton LT; Remst DFG; Wouters AK; Van den Eynde A; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2024; 15():1368290. PubMed ID: 38690288
[TBL] [Abstract][Full Text] [Related]
13. Human IL-15 Inhibits NK Cells Specific for Human NK-92 Cells.
Bergman H; Lindqvist C
Anticancer Res; 2021 Jul; 41(7):3281-3285. PubMed ID: 34230122
[TBL] [Abstract][Full Text] [Related]
14. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.
Xing D; Ramsay AG; Gribben JG; Decker WK; Burks JK; Munsell M; Li S; Robinson SN; Yang H; Steiner D; Shah N; McMannis JD; Champlin RE; Hosing C; Zweidler-McKay PA; Shpall EJ; Bollard CM
J Immunother; 2010 Sep; 33(7):684-96. PubMed ID: 20664358
[TBL] [Abstract][Full Text] [Related]
15.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
16. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Garg TK; Szmania SM; Khan JA; Hoering A; Malbrough PA; Moreno-Bost A; Greenway AD; Lingo JD; Li X; Yaccoby S; Suva LJ; Storrie B; Tricot G; Campana D; Shaughnessy JD; Nair BP; Bellamy WT; Epstein J; Barlogie B; van Rhee F
Haematologica; 2012 Sep; 97(9):1348-56. PubMed ID: 22419581
[TBL] [Abstract][Full Text] [Related]
17. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
Jounaidi Y; Cotten JF; Miller KW; Forman SA
Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
Mimura K; Kamiya T; Shiraishi K; Kua LF; Shabbir A; So J; Yong WP; Suzuki Y; Yoshimoto Y; Nakano T; Fujii H; Campana D; Kono K
Int J Cancer; 2014 Sep; 135(6):1390-8. PubMed ID: 24615495
[TBL] [Abstract][Full Text] [Related]
19. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
20. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
